CNP-104, an Investigational Antigen-Specific Therapy, Demonstrates Evidence of Improved Hepatic Function and Prognostic Risk in a Phase 2A Randomized, Placebo-Controlled Trial in PBC

Authors

• Christopher L. Bowlus
• Adam Elhofy
• Molly Frey
• Derrick McCarthy
• Erik Wambre
• Stephen Caldwell
• Roberto J. Firpi
• Brett Fortune
• Michael Galambos
• Stuart C. Gordon, Henry Ford HealthFollow
• Denise Harnois
• Tarek Hassanein
• Matthew R. Kappus
• Eric Lawitz
• Scott McHenry
• Bhaktasharan Patel
• Raymond Phillips
• Daniel Pratt
• Jatinder Pruthi
• Govarthanan Rajendiran
• Gautham Reddy
• Manuel Rodriguez
• Marina Silveira
• Bobby Zervos
• Paul Peloso
• Eric Gershwin

Recommended Citation

Bowlus CL, Elhofy A, Frey M, McCarthy D, Wambre E, Caldwell S, Firpi RJ, Fortune B, Galambos M, Gordon SC, Harnois D, Hassanein T, Kappus MR, Lawitz E, McHenry S, Patel B, Phillips R, Pratt D, Pruthi J, Rajendiran G, Reddy G, Rodriguez M, Silveira M, Zervos B, Peloso P, Gershwin E. CNP-104, an Investigational Antigen-Specific Therapy, Demonstrates Evidence of Improved Hepatic Function and Prognostic Risk in a Phase 2A Randomized, Placebo-Controlled Trial in PBC. J Hepatol 2026; 84:s313-s314.

Document Type

Conference Proceeding

Publication Date

5-1-2026

Publication Title

J Hepatol

Keywords

Gastroenterology & Hepatology

Volume

84

First Page

s313

Last Page

s314